Overview
No overview information available.
Background
No background information available.
Indication
适用于放射性关节炎、类风湿关节炎、腰肌劳损、肩周炎、四肢扭伤及挫伤等。尚用于牙痛、带状疱疹及术后镇痛等。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Bulleyaconitine A Tablets | 国药准字H20057421 | 化学药品 | 片剂 | 5/19/2020 | |
| Bulleyaconitine Soft Capsules | 国药准字H20031060 | 化学药品 | 胶囊剂 | 7/17/2020 | |
| Bulleyaconitine A for Injection | 国药准字H20060972 | 化学药品 | 注射剂 | 1/29/2021 | |
| Bulleyaconitine A Oral Solution | 国药准字H53022050 | 化学药品 | 口服溶液剂 | 8/31/2020 | |
| Bulleyaconitine A Injection | 国药准字H53021065 | 化学药品 | 注射剂 | 8/12/2020 | |
| Bulleyaconitine A Injection | 国药准字H53021560 | 化学药品 | 注射剂 | 6/30/2020 | |
| Bulleyaconitine A Injection | 国药准字H21023347 | 化学药品 | 注射剂 | 6/4/2020 | |
| Bulleyaconitine A Injection | 国药准字H20043270 | 化学药品 | 注射剂 | 8/4/2020 | |
| Bulleyaconitine A Injection | 国药准字H44025154 | 化学药品 | 注射剂 | 2/12/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||